Hormonal therapies (MHT/HRT), evolved from WHI trials, effectively reduce VMS by 70%–90% and preserve bone density via estrogen receptor modulation, with low-dose transdermal regimens minimizing VTE and breast cancer risks per NAMS/IMS guidelines. Here, ESR1 is linked to breast carcinoma.